- Stocks
- Healthcare
- NYSE: MD

Price (delayed)

$29.69

Market cap

$2.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.09

Enterprise value

$3.35B

The debt has plunged by 52% YoY and by 42% from the previous quarter

The company's EPS rose by 41% YoY and by 4.8% QoQ

The equity is down by 48% YoY but it is up by 2.6% QoQ

Mednax's gross profit has decreased by 12% YoY but it has increased by 7% from the previous quarter

The quick ratio has declined by 43% since the previous quarter and by 25% year-on-year

The gross margin has declined by 7% year-on-year

What are the main financial stats of MD

Market
Valuations
Earnings

Shares outstanding

86.28M

Market cap

$2.56B

Enterprise value

$3.35B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.32

Price to sales (P/S)

1.37

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.83

Revenue

$1.83B

EBIT

-$648.71M

EBITDA

-$630.91M

Free cash flow

$244.74M

Per share
Balance sheet
Liquidity

EPS

-$9.09

Free cash flow per share

$2.9

Book value per share

$8.95

Revenue per share

$21.69

TBVPS

$11.59

Total assets

$2.48B

Total liabilities

$1.72B

Debt

$1.06B

Equity

$766.76M

Working capital

$338.44M

Debt to equity

1.38

Current ratio

2.04

Quick ratio

1.88

Net debt/EBITDA

-1.25

Margins
Efficiency
Dividend

EBITDA margin

-34.4%

Gross margin

26.2%

Net margin

-41.5%

Operating margin

6.2%

Return on assets

-24%

Return on equity

-96.7%

Return on invested capital

-29.6%

Return on capital employed

-30.1%

Return on sales

-35.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Mednax stock price performed over time

Intraday

1.96%

1 week

1.54%

1 month

-1.17%

1 year

48.6%

YTD

20.99%

QTD

-1.53%

How have Mednax's revenue and profit performed over time

Revenue

$1.83B

Gross profit

$479.96M

Operating income

$113.78M

Net income

-$760.13M

Gross margin

26.2%

Net margin

-41.5%

The net income rose by 40% year-on-year and by 4.6% since the previous quarter

The net margin has increased by 38% YoY and by 10% from the previous quarter

MD's operating income is down by 28% year-on-year but it is up by 16% since the previous quarter

The operating margin has declined by 25% year-on-year but it has increased by 9% since the previous quarter

What is Mednax's growth rate over time

What is Mednax stock price valuation

P/E

N/A

P/B

3.32

P/S

1.37

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.83

The company's EPS rose by 41% YoY and by 4.8% QoQ

The P/B is 95% above the 5-year quarterly average of 1.7 and 44% above the last 4 quarters average of 2.3

The equity is down by 48% YoY but it is up by 2.6% QoQ

The stock's price to sales (P/S) is 37% more than its last 4 quarters average of 1.0 but 2.1% less than its 5-year quarterly average of 1.4

The revenue has increased by 6% from the previous quarter but it has decreased by 4.3% YoY

How efficient is Mednax business performance

The company's return on sales rose by 40% YoY and by 8% QoQ

MD's return on equity is down by 37% year-on-year and by 17% since the previous quarter

The ROIC is up by 18% YoY but it is down by 13% from the previous quarter

The ROA has grown by 13% YoY but it has contracted by 9% from the previous quarter

What is MD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for MD.

How did Mednax financials performed over time

The total assets is 45% greater than the total liabilities

The quick ratio has declined by 43% since the previous quarter and by 25% year-on-year

The total assets has declined by 43% year-on-year and by 26% since the previous quarter

The debt is 38% more than the equity

The debt has plunged by 52% YoY and by 42% from the previous quarter

The equity is down by 48% YoY but it is up by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.